Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Original Article

Using gastric juice lncRNA-ABHD11-AS1 as a novel type of biomarker in the screening of gastric cancer

Authors: Yunben Yang, Yongfu Shao, Mengying Zhu, Qier Li, Fang Yang, Xuwen Lu, Chunjing Xu, Bingxiu Xiao, Yanke Sun, Junming Guo

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Long noncoding RNAs (lncRNAs) play vital roles in tumorigenesis. However, the diagnostic values of most lncRNAs are largely unknown. To investigate whether gastric juice lncRNA-ABHD11-AS1 can be a potential biomarker in the screening of gastric cancer, 173 tissue samples and 130 gastric juice from benign lesion, gastric dysplasia, gastric premalignant lesions, and gastric cancer were collected. ABHD11-AS1 levels were detected by reverse transcription-polymerase chain reaction. Then, the relationships between ABHD11-AS1 levels and clinicopathological factors of patients with gastric cancer were investigated. The results showed that ABHD11-AS1 levels in gastric cancer tissues were significantly higher than those in other tissues. Its levels in gastric juice from gastric cancer patients were not only significantly higher than those from cases of normal mucosa or minimal gastritis, atrophic gastritis, and gastric ulcers but also associated with gender, tumor size, tumor stage, Lauren type, and blood carcinoembryonic antigen (CEA) levels. More importantly, when using gastric juice ABHD11-AS1 as a marker, the positive detection rate of early gastric cancer patients was reached to 71.4 %. Thanks to the special origin of gastric juice, these results indicate that gastric juice ABHD11-AS1 may be a potential biomarker in the screening of gastric cancer.
Literature
1.
2.
Nakamura J, Tanaka T, Kitajima Y, Noshiro H, Miyazaki K. Methylation-mediated gene silencing as biomarkers of gastric cancer. World J Gastroenterol. 2014;20:11991–2006.CrossRefPubMedPubMedCentral
3.
4.
5.
Xu C, Shao Y, Xia T, Yang Y, Dai J, Luo L, et al. LncRNA-AC13710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. Tumour Biol. 2014;35:9701–6.CrossRefPubMed
6.
Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5:2318–29.CrossRefPubMedPubMedCentral
7.
Lin X, Yang M, Xia T, Guo J. Increased expression of long noncoding RNA ABHD11-AS1 in gastric cancer and its clinical significance. Med Oncol. 2014;31:42.CrossRefPubMed
8.
Cui L, Zhang X, Ye G, Zheng T, Song H, Deng H, et al. Gastric juice microRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 2013;119:1618–26.CrossRefPubMed
9.
Shao Y, Ye M, Jiang X, Sun W, Ding X, Liu Z, et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. Cancer. 2014;20:3320–8.CrossRef
10.
Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336–9.CrossRefPubMed
11.
Mei D, Song H, Wang K, Lou Y, Sun W, Liu Z, et al. Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. Med Oncol. 2013;30:709.CrossRefPubMed
12.
Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y, et al. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol. 2013;139:437–45.CrossRefPubMed
13.
Liu Z, Shao Y, Tan L, Shi H, Chen S, Guo J. Clinical significance of low expression of FER1L4 in gastric cancer patients. Tumour Biol. 2014;35:9613–7.CrossRefPubMed
14.
Shao Y, Chen H, Jiang X, Chen S, Li P, Ye M, et al. Low expression of lncRNA-HMlincRNA717 in human gastric cancer and its clinical significances. Tumour Biol. 2014;35:9591–5.CrossRefPubMed
15.
16.
Zhang X, Cui L, Ye G, Zhang T, Song H, Xia T, et al. Gastric juice microRNA-421 is a new biomarker for screening cancer. Tumour Biol. 2012;33:2349–55.CrossRefPubMed
17.
Adachi Y, Oshiro T, Mori M, Maehara Y, Sugimachi K. Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol. 1997;4:137–40.CrossRefPubMed
18.
Sugita H, Kojima K, Inokuchi M, Kato K. Long-term outcomes of laparoscopic gastrectomy for gastric cancer. J Surg Res. 2015;193:190–5.CrossRefPubMed
19.
Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study. World J Surg. 2002;26:1160–5.CrossRefPubMed
20.
Tian S, Yu J, Kang W, Ma Z, Ye X, Cao Z, et al. Combined detection of CEA, CA 19–9, CA242 and CA50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pac J Cancer Prev. 2014;15:6295–300.CrossRefPubMed
21.
Koessler T, Roth A, Cacheux W. Early gastric cancer: epidemiology, diagnostic, and management. Rev Med Suisse. 2014;10:1118–22.PubMed
Metadata
Title
Using gastric juice lncRNA-ABHD11-AS1 as a novel type of biomarker in the screening of gastric cancer
Authors
Yunben Yang
Yongfu Shao
Mengying Zhu
Qier Li
Fang Yang
Xuwen Lu
Chunjing Xu
Bingxiu Xiao
Yanke Sun
Junming Guo
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3903-3

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

RETRACTED ARTICLE: Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis

Original Article

LRRC3B is downregulated in non-small-cell lung cancer and inhibits cancer cell proliferation and invasion

Original Article

PAQR3 plays a suppressive role in laryngeal squamous cell carcinoma

Original Article

Contribution of resident and recruited macrophages to the photodynamic intervention of colorectal tumor microenvironment

Original Article

A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage

Original Article

CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits